BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

With $40 million from an investor group led by Chris Garabedian’s PXV fund, newly launched Forge Biologics is building a hybrid company that will offer CDMO services to gene therapy companies while also developing its...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

AM-Pharma raises $52M series C extension  AM-Pharma B.V. raised €47 million ($51.7 million) in an additional close of its series C round, bringing the total funds raised in the round to €163 million. The round...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

Two and a half years after Perceptive Advisors’ Chris Garabedian launched Xontogeny to foster biotech start-ups’ growth, the firm has created a $210 million fund that will invest in companies the accelerator is nurturing through...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...
BC Extra | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he...
BC Innovations | Oct 19, 2017
Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BC Week In Review | Sep 22, 2017
Financial News

Landos spins out of Xontogeny accelerator

On Sept. 21, Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass) with the first $5 million tranche of a $10 million series A round from Perceptive Advisors. CEO...
BC Extra | Sep 21, 2017
Financial News

Landos spins out of Xontogeny accelerator

Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass) and raised the first $5 million tranche of a $10 million series A round from Perceptive Advisors. CEO Josep Bassaganya-Riera...
BC Extra | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) said President and CEO Mark Sirgo will retire at the end of the year. Sirgo will remain vice chairman of the board. The company is seeking a replacement....
Items per page:
1 - 10 of 12
BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

With $40 million from an investor group led by Chris Garabedian’s PXV fund, newly launched Forge Biologics is building a hybrid company that will offer CDMO services to gene therapy companies while also developing its...
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

AM-Pharma raises $52M series C extension  AM-Pharma B.V. raised €47 million ($51.7 million) in an additional close of its series C round, bringing the total funds raised in the round to €163 million. The round...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

Two and a half years after Perceptive Advisors’ Chris Garabedian launched Xontogeny to foster biotech start-ups’ growth, the firm has created a $210 million fund that will invest in companies the accelerator is nurturing through...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...
BC Extra | Aug 14, 2019
Financial News

$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he...
BC Innovations | Oct 19, 2017
Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BC Week In Review | Sep 22, 2017
Financial News

Landos spins out of Xontogeny accelerator

On Sept. 21, Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass) with the first $5 million tranche of a $10 million series A round from Perceptive Advisors. CEO...
BC Extra | Sep 21, 2017
Financial News

Landos spins out of Xontogeny accelerator

Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass) and raised the first $5 million tranche of a $10 million series A round from Perceptive Advisors. CEO Josep Bassaganya-Riera...
BC Extra | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

Neurology company BioDelivery Sciences International Inc. (NASDAQ:BDSI) said President and CEO Mark Sirgo will retire at the end of the year. Sirgo will remain vice chairman of the board. The company is seeking a replacement....
Items per page:
1 - 10 of 12